Akhil Abraham Saji, MD
Akhil Abraham Saji, MD, is a urology resident at New York Medical College/Westchester Medical Center. His interests include urology education and machine learning applications in urologic care. He is a founding and current member of the EMPIRE urology lecture series developed by the American Urological Association New York section.
Articles by Akhil Abraham Saji, MD
One might assume that the AUA meeting is geared toward practicing urologists, but it is also crucial for urologic trainees.
The postsurgical treatment of functional outcomes such as UI and ED after SRP remains a challenge for all urologists.
FDA approval of Adstiladrin for use in BCG-unresponsive nMIBC expands the armamentarium for treatment of high-risk nMIBC.
Drs. David Ambinder and Akhil Saji highlight the importance of attending the AUA meeting as urology residents.
NMIBC-associated costs vary widely across types of treatments utilized, health systems, and regions of the country.
The minimally invasive options available to patients diagnosed with muscle-invasive disease of urothelial origin are limited.
This review highlights the existing research regarding the financial toxicity of advanced prostate cancer.
This review highlights the upcoming plenary sessions of importance in prostate, bladder, kidney, and testicular cancer.
AUA guidelines for localized RCC have thermal ablation as an alternative modality. EAU guidelines are conflicting.
Mutahar Ahmed, MD, discusses the history and current applications of single-port robotic surgery in prostate cancer.
This review highlights the research on the costs related to the treatment of localized PC and the associated outcomes.
BCG plus nogapendekin alfa inbakicept may offer an enhanced treatment option for patients with high-risk NMIBC.
A review of the GÖTEBORG-2 trial and the current recommendations for utilizing mpMRI in prostate cancer screening, ...
An investigation and review of both studies regarding their differences, similarities, and conclusions.
The evidence regarding bisphosphate and denosumab therapy and the impact that bone-protective agents can have on patients.
At the ASTRO 2022 meeting, several authors presented abstracts on postprostatectomy radiation that are worth reviewing.
A detail of the analgesic modalities available for treatment of patients undergoing minimally-invasive urologic surgery.
ASTRO 2022 included several interesting articles about genitourinary cancers, including prostate cancer and bladder cancer.
Stereotactic body radiotherapy can benefit RCC patients deemed unfit for surgical therapy.
1 of 4 will UTUC patients will have a variant histologic subtype such as squamous cell, micropapillary, or neuroendocrine.
670 Madison Ave.
Manalapan, NJ 07726